^
BIOMARKER:

HER-2 underexpression

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
13d
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
13d
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression
|
Oncotype DX Breast Recurrence Score®Test
21d
Our results show that HER2-low-positive tumours can be identified as new subgroup of breast cancer by standardised IHC, distinct from HER2-zero tumours. HER2-low-positive tumours have a specific biology and show differences in response to therapy and prognosis, which is particularly relevant in therapy-resistant, hormone receptor-negative tumours. Our results provide a basis for a better understanding of the biology of breast cancer subtypes and the refinement of future diagnostic and therapeutic strategies.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression • HR negative
23d
P1, N=92, Recruiting, Shanghai Fosun Pharmaceutical Development Co, Ltd. | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1 | Trial primary completion date: Jan 2025 --> Sep 2023
Clinical • Enrollment open • Phase classification • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 underexpression
|
trastuzumab mafodotin (FS-1502)
1m
In this review we report the most relevant molecular targets in BC, ordered pursuant to their pathway and classified in concordance with ESCAT.
Clinical • Review • Journal • Tumor Mutational Burden • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • MSI (Microsatellite instability) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PALB2 (Partner and localizer of BRCA2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRCA1 mutation • BRCA2 mutation • TMB-H • PTEN mutation • HER-2 expression • PTEN deletion • ER mutation • PALB2 mutation • HER-2 underexpression • AKT1 mutation • NTRK fusion
1m
P1, N=292, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Trial completion date: Mar 2020 --> Sep 2021
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
2ms
Conclusions The overexpression of HER2 is associated with lower overall survival in surgically treated patients with intestinal type GC. Therefore, HER2 molecular targeted therapy should be considered for those patients after surgery.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 underexpression
3ms
Compared with IDC, MBC has a better prognosis. For patients with MBC, we identified prognostic factors that can help clinicians better assess patient outcomes and guide individualized treatment.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • HER-2 underexpression
3ms
Using immunohistochemistry and dual-color silver-enhanced in situ hybridization based on the Trastuzumab for a gastric cancer scoring scheme, we evaluated HER2 protein expression, gene amplification, and genetic heterogeneity in three groups (HER2-neg, HER2-low, HER2-pos) of 55 patients. These findings support the hypothesis that low-level HER2 expression and heterogeneity have significant clinical implications in PDAC. HER2 heterogeneity might indicate the best strategies of combination therapies to prevent the development of subdominant clones with resistance potential.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 expression • HER-2 underexpression
|
Herceptin (trastuzumab) • DA 3111 (trastuzumab biosimilar)
3ms
The most commonly used regimens for first- and second-line were combination chemotherapy, which were 74.7% and 65.3%, respectively; paclitaxel (55.6%) and platinum (43.8%) were the most commonly used drugs for the first-line treatment... Based on this observational cohort study, there is no significant difference in the current treatment patterns and prognosis between HER2-low pts and TN pts . However, with the emergence of HER2-targeted ADC therapy, HER2-low ABC pts which were commonly defined as TNBC may benefit from these novel therapies . The recurrence subgroup with DFI≥12 months presented a trend of longer OS, suggesting the therapy mode and response in early stage should be considered in advanced TNBC treatment.
Retrospective data • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
paclitaxel
3ms
In the HER2 low-expressing HT 29 model, however, CX3CL1 overexpression not only prolonged survival time but also overcame trastuzumab resistance in a partly NK cell-dependent manner. Taken together, these findings identify CX3CL1 as a feasible pharmacologic target to enable trastuzumab therapy in HER2 low-expressing cancers and render it a potential predictive biomarker to determine therapy responders.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1)
|
HER-2 positive • HER-2 overexpression • HER-2 expression • HER-2 underexpression
|
Herceptin (trastuzumab)
3ms
To our knowledge this is the only ongoing study evaluating T-DXd with or without endocrine therapy for HR+, HER2-low breast cancer in the neoadjuvant setting . The study will shed light on clinical activity and biomarkers, which may guide larger confirmatory studies for patients with HR+, HER2-low early breast cancer.
Clinical • P2 data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HR positive + HER-2 negative
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • anastrozole
3ms
We identified consecutive patients with ER+ HER2- MBC who received CDK4/6 inhibitor plus either letrozole or fulvestrant between Mar 2017 - Jun 2020 from an institutional cancer registry...The majority received palbociclib (84%) while the rest received ribociclib... In patients with ER+ HER2- MBC treated with CDK4/6 inhibitors, HER2-low expression was associated with an inferior PFS, and may serve as a potential marker candidate for CDK4/6 inhibitor efficacy . As novel anti-HER2 antibody-drug conjugates demonstrated efficacy in HER2-low expressing MBC, coupled with the emerging evidence for the combination of CDK4/6 inhibitors with anti-HER2 agents, this HER2-low expression subgroup warrants prospective evaluations in future trials.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • ER positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HR positive + HER-2 negative
|
Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • letrozole
3ms
Funding: AstraZeneca Background: Breast cancer patients with HER2 low expression by immunohistochemistry (IHC), defined as IHC1+ or IHC2+ without gene amplification (ISH-) do not respond to conventional anti-HER2 therapies such as trastuzumab or pertuzumab . The HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) showed efficacy in late line HER2-overexpressing patients, with some responses in patients with low HER2 expression... HER2 IHC1+/2+ (ISH-) by Ventana 4B5 represent a significant proportion of breast cancer patients and more than 50% of ER+ve and PR+ve subtypes . The 4B5 assay classed several patients as IHC1+/2+ that are IHC0 by Herceptest, but almost all patients IHC0 by 4B5 were also IHC0 by Herceptest.
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 amplification • HER-2 overexpression • ER positive • HER-2 underexpression • PGR positive
|
HercepTest • PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
|
Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
3ms
P1b, N=115, Recruiting, Daiichi Sankyo, Inc. | Trial completion date: Apr 2022 --> May 2023 | Trial primary completion date: Jul 2021 --> Aug 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
BRAF V600E • HER-2 positive • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ROS1 fusion • ALK mutation • ALK-ROS1 fusion
|
Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
4ms
Conclusion MC is a rare subtype of breast cancer. However, it is important to recognize this subtype of breast cancer as it is associated with a prognostically better pathological profile, such as lower tumor grade and Ki67 index, lower frequency of axillary metastasis, higher expression of ER and PR, and lower expression of HER2/neu.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • HER-2 underexpression • ER overexpression
4ms
P2, N=104, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 underexpression
4ms
P2, N=196, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
4ms
T-DXd is likely to become the standard of care for second-line treatment of HER2-positive mBC, and it may play a role in the treatment of hormone receptor-positive and triple-negative mBC with HER2-low expression. Because it was recently approved in the United States and Japan to treat HER2-positive metastatic GC, it holds promise for the treatment of other HER2-positive solid tumors, including colorectal cancer, non-small cell lung cancer, and HER2-low-expressing BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
5ms
HER2-XPAT is a potent, prodrug TCE exhibiting protease-dependent tumor efficacy in mouse xenografts and a wide TI with no CRS in NHPs. XTEN’s low immunogenicity has already been demonstrated in humans (growth hormone and FVIII). HER2-XPAT represents a promising solution for HER2-high tumors with potential expansion to HER2 low expressing tumors.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression • HER-2-H
5ms
 De-novo MBC shows a rate of low HER2-expression comparable with early breast cancer, and significantly lower compared with relapsed MBC. This difference did not appear to be related to the biopsy site. Confirmation of these observations on larger populations of patients is warranted.
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
5ms
 HER2-low expression is highly unstable during disease evolution. Relapse biopsy in case of a primary HER2-0 tumor may open new opportunities for treatment in a relevant proportion of patients.
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 negative • HER-2 expression • HER-2 underexpression
5ms
P3, N=366, Recruiting, RemeGen | Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Dec 2023
Clinical • Enrollment open • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 expression • HER-2 underexpression
|
paclitaxel • docetaxel • capecitabine • vinorelbine tartrate • disitamab vedotin (RC48)
5ms
P2, N=39, Recruiting, MedSIR | Trial primary completion date: Dec 2020 --> Nov 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
5ms
T-DXd was effective even for HER2-low expressing breast and gastric cancer in several clinical studies. Taking advantage of these strong points and synergism with other cytotoxic, molecular-targeted and immunological agents, it is expected that T-DXd will bring further progression in treatment both for strongly and weakly HER2 positive AGC in various treatment settings including perioperative chemotherapy.
Clinical • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • EGFR positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6ms
NPS vaccination with trastuzumab was associated with improved 36-month DFS among patients with TNBC. The observed benefit to this high-risk subgroup warrants confirmation in a phase III trial.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CSF2 (Colony stimulating factor 2)
|
HER-2 expression • HER-2 underexpression
|
Herceptin (trastuzumab) • NeuVax (nelipepimut-S)
7ms
Clinical • P1 data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
7ms
These are new HER2 ADCs and tyrosine kinase inhibitors, such as tucatinib or neratinib. In addition, targeting other members of the HER family is a promising approach to improve outcomes in breast cancer patients. This review gives an overview of treatment strategies in targeting HER2 and other members of the HER family, not only in HER2-positive breast cancer, but also in HER2-low expressing tumors, and of approaches to overcome HER2 resistance.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • EGFR positive
|
Nerlynx (neratinib) • Tukysa (tucatinib)
7ms
P1/2, N=82, Recruiting, Klus Pharma Inc. | Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Apr 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
7ms
P1b, N=185, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Aug 2023
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • HER-2 underexpression • PGR positive • PGR negative
|
paclitaxel • Imfinzi (durvalumab) • capecitabine • fulvestrant • Enhertu (fam-trastuzumab deruxtecan-nxki) • capivasertib (AZD5363) • anastrozole
7ms
HER2-L mCRC showed a better prognosis than HER2-Pos mCRC, and it is similar to HER2-Neg mCRC. Hence, HER2-L mCRC might have different biologic behavior in terms of prognostic value and molecular landscape of mCRC, suggesting the possibility of implementation of HER2-guided clinical development against HER2-expressing mCRC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 mutation • HER-2 expression • HER-2 underexpression
8ms
In conclusion, our study indicates that HER2-positive MSCC is an aggressive disease with unique clinicopathological characteristics. Both HER2-positive status and an SCC component are critical factors for poor prognosis. HER2-positive MSCC and triple-negative MSCC are distinct subgroups. Corresponding targeted therapy recommendations should be made for this HER2-positive MSCC group.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression • EGFR positive
9ms
18 pts had HER2-positive status (12 of 18 failed previous trastuzumab therapy), 2 pts had HER2 mutation and 5 pts had HER2 low expression (without FISH amplification). 2 death cases due to disease progression were reported, both only received one cycle of KN026 plus KN046 due to COVID-19 restriction. Conclusions KN026 combined with KN046 is well tolerated and has demonstrated preliminary albeit profound anti-tumor activity in HER2-positive solid tumors.
Clinical • Late-breaking abstract • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
HER-2 positive • HER-2 amplification • HER-2 overexpression • HER-2 underexpression
|
Herceptin (trastuzumab) • KN046 • KN026
9ms
18 pts had HER2-positive status (12 of 18 failed previous trastuzumab therapy), 2 pts had HER2 mutation and 5 pts had HER2 low expression (without FISH amplification). 2 death cases due to disease progression were reported, both only received one cycle of KN026 plus KN046 due to COVID-19 restriction. Conclusions KN026 combined with KN046 is well tolerated and has demonstrated preliminary albeit profound anti-tumor activity in HER2-positive solid tumors.
Clinical • Late-breaking abstract • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
HER-2 positive • HER-2 amplification • HER-2 overexpression • HER-2 underexpression
|
Herceptin (trastuzumab) • KN046 • KN026
10ms
15 pts had HER2-positive status (11 of 15 failed previous trastuzumab therapy), 1 pts had HER2 mutation and 5 pts had HER2 low expression (without FISH amplification). 2 death cases only received one cycle of KN026 plus KN046 due to COVID-19 restriction before died from clinical deterioration from underlying tumors. Conclusions KN026 combined with KN046 is well tolerated and has demonstrated profound anti-tumor activity in HER2-positive solid tumors.
Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
HER-2 positive • HER-2 amplification • HER-2 overexpression • HER-2 underexpression
|
Herceptin (trastuzumab) • KN046 • KN026
10ms
15 pts had HER2-positive status (11 of 15 failed previous trastuzumab therapy), 1 pts had HER2 mutation and 5 pts had HER2 low expression (without FISH amplification). 2 death cases only received one cycle of KN026 plus KN046 due to COVID-19 restriction before died from clinical deterioration from underlying tumors. Conclusions KN026 combined with KN046 is well tolerated and has demonstrated profound anti-tumor activity in HER2-positive solid tumors.
Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
HER-2 positive • HER-2 amplification • HER-2 overexpression • HER-2 underexpression
|
Herceptin (trastuzumab) • KN046 • KN026
10ms
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ALB (Albumin)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
10ms
Background Margetuximab (M) is an investigational Fc-engineered anti-HER2 monoclonal antibody that targets the same epitope as trastuzumab (T). It has been administered for over 6 years without long-term cumulative safety issues. Combined M plus chemotherapy Q3W demonstrated acceptable safety and tolerability, similar to that for T plus chemotherapy Q3W in Study 04.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
Herceptin (trastuzumab) • Margenza (margetuximab)
10ms
Bevacizumab (BVZ) was the most frequent BT associated to CT (77.8%), mainly with capecitabine and/or paclitaxel (72.2%)...CT in monotherapy was reported in 69.6% pts (capecitabine 31.3%, eribulin 25.0%)... In TN/HER2-low ABC pts, lung, lymph nodes and bone were the most frequent metastatic locations. As opposed to TN subset, HER2+ disease is part of the subtype changes reported. Although the main 1 st - and 2 nd -line therapies were CT and CT/BT, similarly to TN subset, the rate of pts with PD to 1 st - and 2 nd -line therapies is higher, and also those pts treated in the 3 rd -line setting.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HER-2 expression • HER-2 underexpression
|
Avastin (bevacizumab) • paclitaxel • capecitabine • Halaven (eribulin mesylate)
11ms
Clinical • New P1 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • HER-2 underexpression • PGR positive • PGR negative
|
paclitaxel • Imfinzi (durvalumab) • capecitabine • fulvestrant • Enhertu (fam-trastuzumab deruxtecan-nxki) • capivasertib (AZD5363) • anastrozole
12ms
Protein dose of 500 µg is preferable for discrimination between tumors with high and low expression of HER2. Further studies are justified to evaluate if Tc-ADAPT6 can be used as an imaging probe for stratification of patients for HER2-targeting therapy in the areas where PET imaging is not readily available.
P1 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
1year
Clinical • Tumor Mutational Burden • Microsatellite instability • MSi-H Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • MSI (Microsatellite instability) • KMT2D (Lysine Methyltransferase 2D) • KMT2C (Lysine Methyltransferase 2C) • RNF43 (Ring Finger Protein 43)
|
TP53 mutation • MSI-H/dMMR • HER-2 expression • ARID1A mutation • HER-2 underexpression • RNF43 mutation
1year
Enrollment open • Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
BAY2701438 • BAY2701439
1year
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
1year
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ALB (Albumin)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
1year
Of the 28 genes within the 3p14 region, we found significant differential expression for FLNB (lower expression in HER2+ tumours, 5%FDR= 0.03), which has been shown to supress tumour growth and metastasis.Combining admixture mapping and transcriptomics is a promising approach to discover candidate genes associated with subtype-specific breast cancer risk. We are currently working to replicate suggestive findings and expand our sample size to increase power.
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 underexpression • EGFR positive
1year
About 15% of breast cancers are HER2 over-expressing (HER2 IHC 3+ or IHC 2+/ISH+)), but another 45% have low levels of HER2 (HER2 IHC 2+/ISH- or IHC 1+), and these patients are not currently approved for treatment with trastuzumab. Recently, a new HER2 ADC, DS-8201 showed anti-tumor activity, not only in patients with HER2 over-expressing breast cancer but also in HER2 low expressing tumors in whom to date, there are no effective anti-HER2 therapies indicated...Multiplexed quantitative MS could be used to accurately predict which patients will derive the most benefit from Her2-ADC therapy based on the specific biology of their tumor. These studies are ongoing.
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • SLFN11 (Schlafen Family Member 11)
|
HER-2 positive • HER-2 overexpression • EGFR expression • HER-2 underexpression
|
Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
over1year
Clinical • Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
BAY2701438 • BAY2701439
over1year
Clinical • Enrollment open • Combination therapy • PD(L)-1 Biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
BRAF V600E • HER-2 positive • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ROS1 fusion • ALK mutation • ALK-ROS1 fusion
|
Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
over1year
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
BAY2701438 • BAY2701439
over1year
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression • HER-2 mutation • HER-2 underexpression
|
BAY2701438 • BAY2701439